OTSKF OTSUKA HLDGS CO LTD
- 39.480
- 0.0000.00%
- 57.051
- +17.571+44.51%
OTSUKA HLDGS CO LTD News
Global Stocks With the Highest Triple Momentum Analysis – BofA
UBS Initiates OTSUKA HLDGS CO LTD(OTSKF.US) With Buy Rating, Announces Target Price $70.5
Jefferies Maintains OTSUKA HLDGS CO LTD(OTSKF.US) With Buy Rating, Raises Target Price to $67.07
Jefferies Maintains OTSUKA HLDGS CO LTD(OTSKF.US) With Buy Rating, Raises Target Price to $63.94
J.P. Morgan Initiates OTSUKA HLDGS CO LTD(OTSKF.US) With Buy Rating, Announces Target Price $64.34
OTSUKA HLDGS CO LTD To Go Ex-Dividend On December 27th, 2024 With 0.528 USD Dividend Per Share
Otsuka to Acquire U.S. Biotech Jnana for up to $1B in Cash
Jefferies Maintains OTSUKA HLDGS CO LTD(OTSKF.US) With Buy Rating, Raises Target Price to $56.43
OTSUKA HLDGS CO LTD To Go Ex-Dividend On June 27th, 2024 With 0.528 USD Dividend Per Share
AstraZeneca Breast Cancer Therapy Fails in Late-stage Trial
Otsuka Ends Development of Late-stage Alzheimer's Asset
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Vertex Pharma Upgraded at Evercore on Alpine Immune Deal
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Medtronic Blood Pressure Treatment Cleared in U.S.
Vera Gains as Jefferies Upgrades to Buy on Lead Asset
Psychedelic Drugs Market to Break $7B in 2029 Led by These 3 Meds
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Analysis
Price Target
No Data
No Data